Edwards Lifesciences (EW) PT Raised to $125 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/15/2026
- Wall Street ends down, calls for AI slowdown pummel chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Trump slams Anthropic CEO over AI slowdown call
- Oil prices soar over 4% to 16-week high after Saudi strikes
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street ends down, calls for AI slowdown pummel chipmakers
- Citi sees memory market undersupply worsening through 2031
- Global AI stocks fall as industry chiefs call for slowing development
- Enova drops bid to acquire Grasshopper Bancorp, reaffirms guidance
- Baldwin Group to go private in $7.7 billion deal with Sequence and Dell family office
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Edwards Lifesciences (EW) PT Raised to $125 at Leerink Partners
April 27, 2016 12:44 PM EDTLeerink Partners analyst Danielle Antalffy reiterated an Outperform rating and boosted is price target on Edwards Lifesciences (NYSE: EW) to $125.00 (from $115.00) following continued strong results.
Antalffy commented, "Last night, EW reported yet another quarter of better than-expected sales -- now its 8th consecutive quarter of sales outperformance -- with 1Q16 adjusted sales of $695.6M (+18% y/y, +19% ex. FX), coming in ~$27M ahead of us and over $30M ahead of the Street. Again, stronger... More
Edwards Lifesciences (EW) PT Raised to $123 at Piper Jaffray
April 27, 2016 8:14 AM EDTPiper Jaffray analyst Brooks West raised his price target on Overweight-rated Edwards Lifesciences (NYSE: EW) to $123.00 (from $97.00) following another 'beat and raise' quarter.
West commented, "Edwards Lifesciences posted a strong beat-and-raise 1Q16 including revenue of $697.3M vs. consensus $664.2M (+20% y/y) and adjusted EPS of $0.71 vs. consensus... More
Edwards Lifesciences (EW) Tops Q1 EPS by 5c; Issues Solid Outlook
April 26, 2016 4:21 PM EDTEdwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.71, $0.05 better than the analyst estimate of $0.66. Revenue for the quarter came in at $697.3 million versus the consensus estimate of $664.95 million.
"We are very pleased to report a strong start to 2016," said Michael A. Mussallem, chairman and CEO.... More
